The Investor Relations website contains information about Fate Therapeutics, Inc.'s business for stockholders, potential investors, and financial analysts.
Dan KaufmanJust heard this big news: Fate Therapeutics Announces FDA Clearance of Landmark IND for FT500 iPSC-derived, Off-the-Shelf NK Cell Cancer Immunotherapy. ir.fatetherapeutics.com/news-releases/…. Congratulations to the team at Fate. Many great related talks and posters during #ASH18
Jane Mayer on the discovery of e-mail messages from 2015 linking Steve Bannon, Donald Trump’s campaign strategist during his successful Presidential bid, and the Bid Data firm Cambridge Analytica to efforts to pull Great Britain out of the European...
Experts say proliferation of products makes standardization crucial, as ballooning complexity risks overwhelming apheresis centers and forcing service cuts.
Dan KaufmanInteresting perspective if 15 different CAR-T products likely available in next 5 years. Lots of logistical issues. So, more good reasons to be excited about "off-the-shelf" CAR NK cells. No apheresis, no patient matching issues. In trials soon.
Confusion about mesenchymal stem cells is making it easier for people to sell unproven treatments, warn Douglas Sipp, Pamela G. Robey and Leigh Turner.
Dan KaufmanNice report from @LeighGTurner and colleagues about problems with MSCs both in research and Clinic. I agree if people in this field cannot even decide what MSC stands for, then hard to get good understanding.